Gemini Therapeutics is a technology company.
Gemini Therapeutics has raised $45.0M across 2 funding rounds.
Gemini Therapeutics has raised $45.0M in total across 2 funding rounds.
Gemini Therapeutics is a clinical-stage biotechnology company, not a general technology firm, specializing in precision medicine for genetically defined diseases, primarily dry age-related macular degeneration (AMD) and related rare eye disorders.[1][2][3] It develops therapies like recombinant proteins, gene therapies, and monoclonal antibodies targeting complement system dysregulation, serving patients with high unmet needs in ophthalmology, such as those with complement factor H (CFH) variants affecting ~40% of dry AMD cases (6 million patients globally).[1][2] The lead product, GEM103—a recombinant CFH protein—was in Phase 2a trials for dry AMD but has since been discontinued, alongside other pipeline candidates like GEM-307 and various gene therapies; the company invested ~$50 million in R&D in 2024 across AMD, Stargardt Disease, and Retinitis Pigmentosa targets.[1][3] Growth momentum included a 2021 public debut via SPAC merger, but recent developments show pipeline setbacks with multiple discontinuations.[2][3][5]
Founded in 2015 and headquartered in Cambridge, Massachusetts, Gemini Therapeutics emerged to tackle genetic drivers of serious diseases, particularly in ophthalmology.[1][6] Key leadership included CEO Jason Meyenburg, who highlighted the SPAC merger with FS Development Corp. in 2021 as a pivotal moment to access public markets and advance complement-focused precision medicines.[2] The idea stemmed from identifying molecular abnormalities in high-need patients, leading to a multimodal pipeline; early traction built around GEM103's targeted approach for CFH-variant AMD patients, culminating in Phase 2a initiation by 2021.[2][3] The company evolved from private biotech to publicly traded (Nasdaq: GMTX) via the SPAC, emphasizing trial enrichment with genetically defined cohorts.[2][5]
Gemini rides the precision medicine wave in biotech, leveraging genetic profiling to address unmet needs in age-related diseases amid an aging global population driving AMD prevalence (15 million dry AMD cases).[1][2] Timing aligns with advances in gene therapy and complement biology, fueled by market forces like rising ophthalmology demand and regulatory nods for targeted therapies (e.g., post-2020 trial accelerations).[3] It influences the ecosystem by validating genetically enriched trials, partnering (e.g., StrideBio), and contributing to complement-targeted innovation, though discontinuations highlight biotech risks in high-failure fields like rare diseases.[2][3][6]
Pipeline discontinuations (e.g., GEM103, gene therapies) signal challenges, potentially shifting Gemini toward repivoting its precision platform or acquisition amid biotech funding pressures.[3][5] Trends like AI-driven genetics and next-gen complement inhibitors could revive momentum if leveraged, evolving its role from AMD pioneer to broader rare disease player. As a public entity post-SPAC, strategic partnerships or pipeline reboots will define influence, tying back to its mission of genetic breakthroughs for serious diseases.[1][2]
Gemini Therapeutics has raised $45.0M in total across 2 funding rounds.
Gemini Therapeutics's investors include Access Biotechnology, Advanced Technology Ventures, Atlas Venture, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, OrbiMed, The Column Group, Versant Ventures.
Gemini Therapeutics has raised $45.0M across 2 funding rounds. Most recently, it raised $43.0M Series A in October 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2017 | $43.0M Series A | Access Biotechnology, Advanced Technology Ventures, Atlas Venture, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, OrbiMed, The Column Group, Versant Ventures | |
| Apr 1, 2016 | $2.0M Seed | Access Biotechnology, Advanced Technology Ventures, Atlas Venture, Avoro Ventures, Chris, Frazier Healthcare Partners, Longwood Fund, OrbiMed, The Column Group, Versant Ventures |